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RibavirinAbstract Background: The contribution of the host immune response to sustained virologic
response (SVR) is not clear in children with chronic hepatitis C (CHC). It is still unknown whether
TLRs 7&8 expression in monocytes is related to disease progression in HCV infected children or
whether it represents a protective factor in those patients who are slow disease-progressors.
Objective: The aim of this study was to assess the value of expression of TLRs 7&8 and TNF as a
predictor for the outcome of antiviral therapy in children with CHC.
Patients and methods: This prospective study included fifty CHC children aged 5–18 years. Thirty-
four were males, sixteen were females who received Peg-IFN-a-2b and RBV for 48 weeks. mRNA
levels of TLRs 7&8 in monocytes were evaluated using real-time PCR before a 48-week treatment
with Peg-IFN-a-2b and RBV. In addition, we studied tumor necrosis factor (TNF) production in
monocytes using three-color immunofluorescence and flow cytometry after TLRs 7&8 ligand Resi-
quimod (R848) stimulation.
Results: According to the virological response of the treatment, the infected children were classified
into sustained virological response (SVR) 72% and non-responder 28%. The study determined that
mRNA levels of TLRs 7&8 were significantly high in SVR compared to non-responders. Further-
more, after stimulation with R848 the median fluorescence intensity (MFI) for TNF protein was
significantly high in SVR compared to non-responders.
Conclusions: TLRs 7&8 and TNF have great importance in controlling HCV infection and the
responses to IFN therapy. Further research covering other stages of CHC at large numbers and
at different monocytes subsets levels will be needed.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Pediatric
Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).-Koom,
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The World Health Organization has declared hepatitis C as a
global health problem, with approximately 3% of the world’s
population (roughly 170–200 million people) infected with
HCV. Egypt has the highest prevalence of HCV in the world,
ranging from 6% to 28% with an average of approximately
13.8% in the general population.1
TLRs play an important role in innate immune mechanisms
that form the first line of defense against invading pathogens.
TLRs are a group of pattern-recognition receptors (PRRs) rec-
ognizing conserved molecular motifs also named pathogen-
associated molecular patterns (PAMPs). Recognition of
PAMPs by TLRs not only activates the innate immune system
but also activates pathways important for acquired immunity.
TLRs typically are type I transmembrane proteins composed
of three different domains; an extracellular domain (ECD)
characterized by a horseshoe shape containing a large number
of leucine-rich repeats (LRRs) of 20–30 amino acids important
for the recognition of PAMPs, a transmembrane domain and
an intracellular Toll/interleukin-1 receptor (TIR) domain that
initiates intracellular signaling.2
The importance of innate immunity in HCV infection is
becoming increasingly apparent.3 Monocytes, the precursors
of macrophages and dendritic cells, are involved in the innate
immune response via cognate interactions and the production
of pro-inflammatory cytokines, such as IFNs and interleukins
(IL-12, IL-6 and TNF-a). In particular, TLRs that are
expressed on monocytes can signal cytokine release, cellular
activation, and upregulation of the major histocompatibility
(MHC) Class I or Class II,4 and thus help link the innate
and the adaptive immune responses. TLRs 7&8 are members
of the toll like family of receptors,5 which recognize single-
stranded viral RNA (ssRNA),6 lead to NF-B activation, and
promote the production of cytokines such as IL-12 and
TNF-a.7 TLR7 and TLR9 agonists have been shown to have
clinical efficacy against HCV. It is still unknown whether
TLRs 7&8 expression in monocytes is related to disease pro-
gression in HCV infected children or whether it represents a
protective factor in those patients who are slow disease-
progressors.8
Objective
The aim of this study was to assess the value of expression of
TLRs 7&8 and TNF as a predictor for the outcome of antiviral
therapy in children with CHC.
Patients and Methods
Study Population
Fifty children with clinically and laboratory diagnosed CHC
(ages 5–18 years, 34 males and 16 females), attending the out-
patient clinic of the National Liver Institute, Menoufia Univer-
sity, Egypt were included. A detailed clinical history and a
complete physical examination were carried out for each
patient. None of the patients had received antiviral treatment
before entering into the study, in order to avoid the possible
effect of therapy on the expression of TLRs (such effect hasbeen described by Vollmer et al.9). Routine laboratory meth-
ods were used to determine serum alanine aminotransferase
(ALT), aspartate aminotransferase (AST) viral load in HCV
patients.
Criteria for inclusion were children aged 3–18 years with
compensated chronic HCV infection (HCV-RNA positive by
PCR for more than 6 months), whose hemoglobin (Hb) was
P10 g/dL, absolute neutrophil count (ANC) >1500/mm3,
platelet count >75,000/mm3, and who had normal random
blood sugar, serum creatinine, serum ferritin, thyroid function
tests and lipid profile and no other associated liver disease
[autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin
deficiency, hepatitis B virus (HBV) infection]. Liver biopsy
was mandatory for enrollment. Patients with decompensated
cirrhosis, any other cause of liver disease associating HCV
infection, body mass index (BMI) P95 percentile, severe
psychiatric conditions, uncontrolled seizure disorder,
decompensated cardiovascular disease, renal insufficiency,
evidence of retinopathy, decompensated thyroid disease,
hemoglobinopathy, immunologically mediated diseases or
any other chronic illness requiring long term immunosuppres-
sive drugs or previous IFN therapy within 1 year of enroll-
ment, were excluded from the study. The duration of therapy
for those who completed the course was 48 weeks. Virological
responses of therapy were defined as reported by Ghany
et al.,10. Patients were administered Peg-IFN-a-2b (PegIntron)
at a dosage of 60 lg/m2 per week subcutaneously and RBV
15 mg/kg per day orally for 48 weeks. Real-time PCR for
HCV-RNA was performed using COBAS Ampliprep/
COBAS TaqMan, Roche Molecular Systems, Inc., Branch-
burg, NJ, 08876 United States (the detection limit was 15 IU/
ml) at the baseline, 12th, 24th and 48th weeks during treat-
ment, and after 24 weeks of end of treatment (study week 72).
The doses of PEG-IFN-a-2b and RBV were modified
according to absolute neutrophilic count (ANC), hemoglobin
and platelets. If Hb dropped to <10 gm/dL, RBV dose was
reduced by 25% and if to <7.5 mg/dL, erythropoietin was
administered. If ANC was 500–800/mm3 and/or platelet count
<80,000/mm3, the IFN dose was reduced by 25%. If ANC
was 300–500/mm3, the IFN dose was reduced by 50%. If
ANC <300/mm3 and/ or platelet count 650,000/mm3, the
IFN dose was skipped and resumed later after the count
reached safe levels.
HCV genotyping
HCV genotyping/subtyping was done by restriction fragment
length polymorphism analysis, using restriction enzymes
Hae III, Rsa I, Mva I and Hinf I on PCR-amplified
50-untranslated region.
Liver biopsy and histopathological evaluation
Liver biopsy was performed for all patients except one who
had hemophilia. Hepatic necroinflammatory activity and liver
fibrosis were evaluated according to Ishak staging and grading
scores.11 Necroinflammatory activity was classified into mild
(score 1–5), moderate (score 6–8), and severe (score 9–18).
Fibrosis was classified into mild (stage 1), moderate (stages
2–3), and severe fibrosis or cirrhosis (stages 4–6).12
Table 1 Demographic, laboratory, virological and histopathological characteristics of CHC children.
SVR (n= 36) mean ± SD Non-responders (n= 14) mean ± SD P-value
Sex (males) 69.4% 64.3% 0.746
Age (years) 11.6 ± 3.4 10.4 ± 3.2 0.288
ALT (IU/ml) 60.2 ± 21.2 56.9 ± 18.7 0.522
AST (IU/ml) 55.0 ± 32.6 55.2 ± 15.9 0.218
PT Conc. 82.7 ± 10.9 85.1 ± 14.8 0.329
Fibrosis 1.66 ± 0.67 1.57 ± 0.75 0.568
Activity 4.25 ± 0.93 4.21 ± 0.97 0.799
HCV-RNA (IU/ml) 7056751.1 ± 179119.5 1754376.9 ± 471566.0 <0.001
Genotype
4a 31 (86.1%) 11 (85.7%) 0.97
4b 5 (13.9%) 2 (14.3%)
8 M.A. Khedr et al.At baseline, peripheral blood mononuclear cells (PBMCs)
were isolated from buffy coats of heparinized blood by
Ficoll-Hypaque (Amersham Biosciences) density gradient cen-
trifugation; monocytes were further isolated using CD14+-
conjugated magnetic beads (Miltenyi Biotech, Germany) for
the positive selection according to the manufacturer’s instruc-
tions. Monocytes were cultured in RPMI 1640 (Sigma Diag-
nostic Louis, Mo.) and stimulated with TLRs 7&8 ligand
R848 (made up at a concentration of 1 mg/ml in sterile
endotoxin-free water; InvivoGen, San Diego, California) at
1 lg/ml,7 or medium alone (controls) in cultures at 37 C,
5% CO2 for 6 h in the presence of 10 lg/ml Brefeldin A
(Sigma, Germany). For the detection of intracellular TNF,
the stimulated cells were permeabilized with Perm/Wash solu-
tion (BD Biosciences, PharMingen) and stained with
PE-conjugated anti-TNF Ab (Caltag, Germany) and
PE-conjugated rat IgG1 (Caltag, Germany) as isotype control.
The cells were analyzed by flow cytometry.
Total RNA was extracted from monocytes using the
RNeasy Protect Mini Kit (QIAGEN) according to the manu-
facturer’s protocol and reverse-transcribed as for conventional
RT-PCR (Roche Diagnostics, Germany). cDNA was used for
amplification in the SYBR green format using the
LightCyclerFastStart DNA Master SYBR Green (Roche
Diagnostics, Germany). The following primer pairs were used:
TLR7 50 primer, 50-TTA ACC TGG ATG GAA ACC AGC
TA-30 and 30 primer, 50-TCA AGG CTG AGA AGC TGT
AAG CTA-30 and TLR8 50 primer, 50-TGT TAT GAC AGC
AGA GGG TGA TG-30 and 30 primer, 50-GAG TTG AAA
AAG GAG GTT ATA GGA TAA ATC-30. As an internal
control the housekeeping gene a-enolase was amplified.
Statistical analysis
Values were expressed as mean ± standard deviation or num-
ber (percentage) of individuals with a condition. For quantita-
tive data, statistical significance was tested by either
independent samples t-test or by non-parametric Mann-
Whitney U test according to the nature of the data. For qual-
itative data, significance was tested by Chi-square test or Fis-
cher’s exact test. Correlation was tested by Sperman’s test.
The diagnostic performance of TLR 7, TLR8 and TNF and
the level of HCV-RNA for differentiation between responders
and non-responders were assessed by calculating the area
under the receiver-operating characteristic (ROC) curves.
The cutoff values for optimal clinical performance weredetermined from the ROC curves. The diagnostic performance
was presented as sensitivity, specificity, negative predictive
value (NPV), positive predictive value (PPV), and accuracy.
Results were considered significant if P-value was 60.05. Sta-
tistical analysis was performed using SPSS, version 13 (SPSS
Inc, Chicago, IL, USA).
Results
The baseline characteristics of patients were comparable
between SVR (n= 36) and non-responders (n= 14) and all
patients had genotype 4 (Table 1). The average mRNA level
was higher by 3.5- and 2-folds for TLR7 and TLR8 respec-
tively in SVR as compared with non-responders at baseline
(P< 0.0001). Induction of inflammatory cytokines with acti-
vation of innate and adaptive immunity is the main event in
TLR signaling.4
To evaluate the relationship between TNF production by
monocytes and TLRs 7&8 mRNA, we measured baseline
TNF expression of monocytes in CHC patients after R848
stimulation at 1 lg/ml for 6 h in the presence of Brefeldin A
and stained the cells for CD14 and TNF. As shown in
Fig. 1, the average MFI was 158.3 ± 20.5 channels in the
SVR monocytes while the non-responders monocytes
expressed TNF with a MFI of 69.2 ± 13.7 channels
(P< 0.001); i.e., the signal for TNF protein was 2.5-fold
higher in SVR monocytes. We did not observe any correlation
between TLR and ALT, viral load or TNF (Table 2).
Cutoff points for variables showing significant associations
with treatment response were analyzed by the receiver operat-
ing characteristic (ROC) analysis. Different cutoff points were
as shown in Fig. 2. For TLR7 it was found that at a cutoff
value of >3.25, it can predict treatment response by 91.7%
sensitivity, 78.6% specificity, 91.7% PPV, 78.6% NPV, and
accuracy of 88%. While TLR8 and TNF at cutoff values
>2.25 and >95 MFI respectively, can predict treatment
response with a sensitivity of 97.2% and 100%, specificity of
100% and 92.9%, PPV of 97.2% and 97.3%, NPV of 93.3%
and 100%, and accuracy of both 98%.Discussion
Predictors of response were early viral response, lower baseline
HCV-RNA levels, female sex, non-maternal route of transmis-
sion of HCV, absence of steatosis on liver histology, and mod-
Figure 1 Comparison of TLR7, TLR8 and TNF levels in SVR and non-responders. TLR7, TLR8 and TNF were highly significant
(P< 0.0001); higher in SVR group than non-responder group (TLR7 mean ± SD 4.4583 ± 0.73070 vs. 2.75 ± 0.89), (TLR8 mean ± SD
4.0139 ± 0.92956 vs. 1.53 ± 0.36), (TNF mean ± SD 158.3333 ± 20.59820 vs. 69.28 ± 13.70).
Table 2 Correlation between TLR 7, TLR 8 and TNF and
age, laboratory and histopathology characters of CHC
children.
TLR 7 TLR 8 TNF (MFI)
r P-value r P-value r P-value
Age 0.216 0.132 0.309 0.029 0.019 0.894
ALT 0.119 0.410 0.104 0.473 0.023 0.894
AST 0.168 0.245 0.179 0.213 0.162 0.261
PT 0.037 0.801 0.093 0.520 0.135 0.351
Fibrosis 0.059 0.686 0.082 0.569 0.134 0.354
Activity 0.002 0.986 0.073 0.613 0.019 0.896
HCV-RNA 0.090 0.535 0.140 0.332 0.223 0.120
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sufficient, and other predictive factors are needed. TLRs 7&8
are members of TLR family which is directly involved in the
recognition of specific viral components, regulation of immune
response and clearance of the invading organisms and their
activation by microbial components leads to the production
of cytokines and IFNs.14,15
If TLRs 7&8 are associated with the recognition of specific
viral components, it is important to characterize their expres-
sion in the monocytes of patients with CHC infection to
further understand pathogen–host interactions and predict
the outcomes. This study to our knowledge represents the first
analysis of the expression of TLRs 7&8 in monocytes of the
Egyptian children with CHC. Unlike liver-biopsy specimens,
monocytes can be easily collected, collection can be repeatedas necessary and they exhibit a broader repertoire and express
higher levels of TLRs mRNA compared with other tissues in
humans.16
The current study found that all patients had genotype 4.
SVR in our study achieved 36/50 (72%). Wirth et al.,17 found
that CHC children with genotype 4 had 80% SVR. In a sys-
tematic review, Hu et al.,18 reported that SVR rates in children
with CHC ranged from 30% to 100%, comparable to those
seen among adults. Schwarz et al.,19 found 53% SVR in chil-
dren treated with PEG-a-2a and ribavirin in USA. On the
other hand El-Naghi et al.,13 reported a lower SVR 23.9% in
Egyptian CHC children.
The current study showed no statistical significant differ-
ence between SVR and non-responder as regards sex, age, liver
enzymes and degree of fibrosis and necro-inflammatory activ-
ity of histopathology. On the other hand, a highly significant
difference was found as regards viral load. The same observa-
tion for all parameters except for viral load was reported by
Abdel-Aziz et al.,20 and Rosen et al.,21. Factors correlated with
a sustained response to combination therapy with pegylated
interferon and ribavirin in hepatitis C dependent on (1) Viral
factors: [Genotypes 2 and 3 (versus genotype 1), lower viral
levels, greater quasispecies diversity, acute versus chronic
infection] and (2) Host factors: [Female sex, younger age, less
fibrosis, lower body weight and body mass index Non-African-
American race and absence of significant co-morbidities (alco-
hol abuse, renal disease, HIV infection)].22
We demonstrated that TLRs 7&8 mRNA levels are signif-
icantly high in SVR compared to non-responders. This result is
in agreement with the result of Taylor et al., who demonstrated
Figure 2 Diagnostic performance of pretreatment parameters for differentiation between responders and non-responders. Receiver-
operating characteristic (ROC) curves of (A) TLR7, (B) TLR8, (C) TNF, level for differentiation between responders and non-responders.
The arrows indicate the cutoff values. AUROC: area under ROC. Cutoff points for variables showing significant associations with
treatment response were analyzed by the receiver operating characteristic (ROC) analysis. For TLR7 it was found that at a cutoff value of
>3.25, it can predict treatment response by 91.7% sensitivity, 78.6% specificity, 91.7% PPV, 78.6% NPV, and accuracy of 88%. While
TLR8 and TNF at cutoff values >2.25 and >95 MFI respectively, they can predict treatment response with a sensitivity of 97.2% and
100%, specificity of 100% and 92.9%, PPV of 97.2% and 97.3%, NPV of 93.3% and 100%, and accuracy of both 98%.
10 M.A. Khedr et al.a decreased level of TLR 7 in non-responders.23 On the other
hand, the result of our study is different from the study of
Dolganiuc et al., who showed that TLR 7 mRNA is signifi-
cantly down regulated in CHC patients.24 This difference
could be explained by the difference in viral genotypes, other
associated viral infection, different methodological approaches,
different clinical stages and the age of the patients. The expres-
sion of gene is a yield of multiple processes which is reflected
by post transcriptional process and other regulatory influences.25
Consequently, mRNA levels of TLRs do not usually represent
the actual expressed protein level,26 so it is recommended to
study the TLR protein expression level as well.
Then, we analyzed whether the variation of TLRs 7&8
mRNA is correlated with the levels of serum HCV-RNA.
Our result shows that patients with SVR have a tendency oflower viral load in comparison to non-responders but it is
not statistically significant. This result is in agreement with
the result of He et al., who found no association between viral
load and the expression level of TLRs.14
Given that TLRs 7&8 receptors on monocytes can recog-
nize viral ssRNA and thus mediate antiviral immune response.
We considered whether the stimulation of TLRs 7&8 with
R848 can initiate differential immune responses between
patients with SVR and non-responders. Several studies
reported conflicting results about the pro inflammatory cytoki-
nes at the vitro levels or the circulating levels during HCV
infection.27 Therefore, we studied TNF production in mono-
cytes of SVR and non-responder before IFN therapy after
stimulating with R848. The MFI for TNF protein was signif-
icantly high in SVR compared to non-responders. Our result
Predictors to ‘‘response” interferon and ribavirin treatment 11is different from the previous result by Marei et al.,28 they
found that TNF production in the non-responders was around
one and half increase than that shown by SVR. This difference
could be explained by the difference of ligand used for stimu-
lation lipopolysaccharide (LPS) of monocytes, age of the
patients and studied monocytes subsets.Conclusion
TLRs 7&8 and TNF have great importance in controlling
HCV infection and the responses to IFN therapy. Further
research covering other stages of CHC at large numbers and
at different monocyte subset levels will be needed.Funding
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